# Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia

> **NCT00528450** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** idarubicin
- **DRUG:** tretinoin

## Key facts

- **NCT ID:** NCT00528450
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2016-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528450, "Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00528450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*